MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: Reference to striatonigral degeneration

Experimental Neurology

Volumn 185, Issue 1, 2004, Pages 47-62

  Fernagut, P O ^a   Diguet, E ^a   Bioulac, B ^a   Tison, F ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

3 NP; Astrocytic activation; Motor behavior; Mouse; MPTP; Striatonigral degeneration

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROPROPIONIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BALANCE DISORDER; BEHAVIOR DISORDER; BRAIN INJURY; CELL ACTIVATION; CELL LOSS; CONTROLLED STUDY; DISEASE DURATION; DISEASE MODEL; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DYSTONIA; GAIT; HINDLIMB; HISTOPATHOLOGY; INCIDENCE; INTOXICATION; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NERVE CELL; NERVE ENDING; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION; STRIATONIGRAL DEGENERATION; SYMPTOM; TASK PERFORMANCE;

EID: 0346993599     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2003.09.014     Document Type: Article

References (61)

1. Ali S.F., David S.N., Newport G.D., Cadet J.L., Slikker W. Jr. MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse. 18:1994;27-34.
2. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev., Neurosci. 2:2001;325-334.
3. Beal M.F., Ferrante R.J., Henshaw R., Matthews R.T., Chan P.H., Kowall N.W., Epstein C.J., Schulz J.B. 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice. J. Neurochem. 65:1995;919-922.
4. Blin O., Desnuelle C., Rascol O., Borg M., Peyro Saint Paul H., Azulay J.P., Bille F., Figarella D., Coulom F., Pellissier J.F.et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J. Neurol. Sci. 125:1994;95-101.
5. Blum D., Gall D., Cuvelier L., Schiffmann S.N. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. NeuroReport. 12:2001;1769-1772.
6. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65:2001;135-172.
7. Brouillet E., Guyot M.C., Mittoux V., Altairac S., Conde F., Palfi S., Hantraye P. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem. 70:1998;794-805.
8. Brouillet E., Conde F., Beal M.F., Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59:1999;427-468.
9. Buisson A., Pateau V., Plotkine M., Boulu R.G. Nigrostriatal pathway modulates striatum vulnerability to quinolinic acid. Neurosci. Lett. 131:1991;257-259.
10. Burn D.J., Jaros E. Multiple system atrophy: cellular and molecular pathology. Mol. Pathol. 54:2001;419-426.
11. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19:1999;3248-3257.
12. Chapman A.G., Durmuller N., Lees G.J., Meldrum B.S. Excitotoxicity of NMDA and kainic acid is modulated by nigrostriatal dopaminergic fibres. Neurosci. Lett. 107:1989;256-260.
13. Coggeshall R.E. A consideration of neural counting methods. Trends Neurosci. 15:1992;9-13.
14. D'Hooge R., Hartmann D., Manil J., Colin F., Gieselmann V., De Deyn P.P. Neuromotor alterations and cerebellar deficits in aged arylsulfatase A-deficient transgenic mice. Neurosci. Lett. 273:1999;93-96.
15. Dulawa S.C., Grandy D.K., Low M.J., Paulus M.P., Geyer M.A. Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J. Neurosci. 19:1999;9550-9556.
16. Fearnley J.M., Lees A.J. Striatonigral degeneration. A clinicopathological study. Brain. 113:1990;1823-1842.
17. Ferger B., Eberhardt O., Teismann P., de Groote C., Schulz J.B. Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation. J. Neurochem. 73:1999;1329-1332.
18. Fernagut P.O., Diguet E., Jaber M., Bioulac B., Tison F. Dopamine transporter knock-out mice are hypersensitive to 3-nitropropionic acid-induced striatal damage. Eur. J. Neurosci. 15:2002;2053-2056.
19. Fernagut P.O., Diguet E., Labattu B., Tison F. A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J. Neurosci. Methods. 113:2002;123-130.
20. Fernagut P.O., Diguet E., Stefanova N., Biran M., Wenning G.K., Canioni P., Bioulac B., Tison F. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neuroscience. 114:2002;1005-1017.
21. Francis J.W., Von Visger J., Markelonis G.J., Oh T.H. Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in mouse striatum. Neurotoxicol. Teratol. 17:1995;7-12.
22. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates. first ed. 1997;Academic Press, New York.
23. Gahtan E., Auerbach J.M., Groner Y., Segal M. Reversible impairment of long-term potentiation in transgenic Cu/Zn-SOD mice. Eur. J. Neurosci. 10:1998;538-544.
24. Georgievska B., Kirik D., Bjorklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp. Neurol. 177:2002;461-474.
25. Gerlach M., Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 103:1996;987-1041.
26. Ghorayeb I., Puschban Z., Fernagut P.O., Scherfler C., Rouland R., Wenning G.K., Tison F. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. Exp. Neurol. 167:2001;133-147.
27. Gould D.H., Gustine D.L. Basal ganglia degeneration, myelin alterations, and enzyme inhibition induced in mice by the plant toxin 3-nitropropanoic acid. Neuropathol. Appl. Neurobiol. 8:1982;377-393.
28. Gu M., Gash M.T., Cooper J.M., Wenning G.K., Daniel S.E., Quinn N.P., Marsden C.D., Schapira A.H. Mitochondrial respiratory chain function in multiple system atrophy. Mov. Disord. 12:1997;418-422.
29. Jakel R.J., Maragos W.F. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci. 23:2000;239-245.
30. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Spooren W., Fuss B., Mallon B., Macklin W.B., Fujiwara H., Hasegawa M., Iwatsubo T., Kretzschmar H.A., Haass C. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 3:2002;583-588.
31. Lantos P.L. The definition of multiple system atrophy: a review of recent developments. J. Neuropathol. Exp. Neurol. 57:1998;1099-1111.
32. Maragos W.F., Jakel R.J., Pang Z., Geddes J.W. 6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions. Exp. Neurol. 154:1998;637-644.
33. Maragos W.F., Zhu J., Chesnut M.D., Dwoskin L.P. Mitochondrial toxin inhibition of [(3)H]dopamine uptake into rat striatal synaptosomes. Biochem. Pharmacol. 63:2002;1499-1505.
34. Matsuura K., Kabuto H., Makino H., Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods. 73:1997;45-48.
35. McLaughlin B.A., Nelson D., Erecinska M., Chesselet M.F. Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J. Neurochem. 70:1998;2406-2415.
36. Moy L.Y., Zeevalk G.D., Sonsalla P.K. Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures. J. Neurochem. 74:2000;1656-1665.
37. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
38. Nishino H., Kumazaki M., Fukuda A., Fujimoto I., Shimano Y., Hida H., Sakurai T., Deshpande S.B., Shimizu H., Morikawa S., Inubushi T. Acute 3-nitropropionic acid intoxication induces striatal astrocytic cell death and dysfunction of the blood-brain barrier: involvement of dopamine toxicity. Neurosci. Res. 27:1997;343-355.
39. Obata T. Dopamine efflux by MPTP and hydroxyl radical generation. J. Neural Transm. 109:2002;1159-1180.
40. Ozaki N., Nakahara D., Kaneda N., Kiuchi K., Okada T., Kasahara Y., Nagatsu T. Acute effects of 1-methyl-4-phenylpyridinium ion (MPP+) on dopamine and serotonin metabolism in rat striatum as assayed in vivo by a micro-dialysis technique. J. Neural Transm. 70:1987;241-250.
41. Papp M.I., Kahn J.E., Lantos P.L. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci. 94:1989;79-100.
42. Reinhard J.F. Jr., Miller D.B., O'Callaghan J.P. The neurotoxicant MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) increases glial fibrillary acidic protein and decreases dopamine levels of the mouse striatum: evidence for glial response to injury. Neurosci. Lett. 95:1988;246-251.
43. Reynolds D.S., Carter R.J., Morton A.J. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J. Neurosci. 18:1998;10116-10127.
44. Roberts R.C., Ahn A., Swartz K.J., Beal M.F., DiFiglia M. Intrastriatal injections of quinolinic acid or kainic acid: differential patterns of cell survival and the effects of data analysis on outcome. Exp. Neurol. 124:1993;274-282.
45. Robinson S., Freeman P., Moore C., Touchon J.C., Krentz L., Meshul C.K. Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. Exp. Neurol. 180:2003;74-87.
46. Rollema H., Damsma G., Horn A.S., De Vries J.B., Westerink B.H. Brain dialysis in conscious rats reveals an instantaneous massive release of striatal dopamine in response to MPP+. Eur. J. Pharmacol. 126:1986;345-346.
47. Rosen G.D., Harry J.D. Brain volume estimation from serial section measurements: a comparison of methodologies. J. Neurosci. Methods. 35:1990;115-124.
48. Ryu J.K., Nagai A., Kim J., Lee M.C., McLarnon J.G., Kim S.U. Microglial activation and cell death induced by the mitochondrial toxin 3-nitropropionic acid: in vitro and in vivo studies. Neurobiol. Dis. 12:2003;121-132.
49. Scherfler C., Puschban Z., Ghorayeb I., Goebel G.P., Tison F., Jellinger K., Poewe W., Wenning G.K. Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). Neuroscience. 99:2000;43-54.
50. Scotcher K.P., Irwin I., DeLanney L.E., Langston J.W., Di Monte D. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4- phenylpyridinium ion on ATP levels of mouse brain synaptosomes. J. Neurochem. 54:1990;1295-1301.
51. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125:2001;109-125.
52. Stefanova N., Puschban Z., Fernagut P.O., Brouillet E., Tison F., Reindl M., Jellinger K.A., Poewe W., Wenning G.K. Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). Acta Neuropathol. (Berl). 106:2003;157-166.
53. Teismann P., Tieu K., Cohen O., Choi D.K., Wu du C., Marks D., Vila M., Jackson-Lewis V., Przedborski S. Pathogenic role of glial cells in Parkinson's disease. Mov. Disord. 18:2003;121-129.
54. Teunissen C.E., Steinbusch H.W., Angevaren M., Appels M., de Bruijn C., Prickaerts J., de Vente J. Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation. Neuroscience. 105:2001;153-167.
55. Tison F., Wenning G.K., Daniel S.E., Quinn N. The pathophysiology of parkinsonism in multiple system atrophy. Eur. J. Neurol. 2:1995;435-444.
56. Venero J.L., Romero-Ramos M., Revuelta M., Machado A., Cano J. Intrastriatal quinolinic acid injections protect against 6-hydroxydopamine- induced lesions of the dopaminergic nigrostriatal system. Brain Res. 672:1995;153-158.
57. Wenning G.K., Ben Shlomo Y., Magalhaes M., Daniel S.E., Quinn N.P. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. 117:1994;835-845.
58. Wenning G.K., Granata R., Laboyrie P.M., Quinn N.P., Jenner P., Marsden C.D. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. Mov. Disord. 11:1996;522-532.
59. Wenning G.K., Tison F., Ben Shlomo Y., Daniel S.E., Quinn N.P. Multiple system atrophy: a review of 203 pathologically proven cases. Mov. Disord. 12:1997;133-147.
60. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22:2002;1763-1771.
61. Zeevalk G.D., Derr-Yellin E., Nicklas W.J. Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade. J. Pharmacol. Exp. Ther. 275:1995;1124-1130.